Eli Lilly (LLY) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2195769/eli-lilly-lly-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2195769
Dec 08, 2023 - The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.
0
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
0
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
https://www.zacks.com/stock/news/2193345/is-it-a-good-idea-to-invest-in-ac-immune-aciu-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2193345
Dec 05, 2023 - Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
0
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151
Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
0
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
https://www.zacks.com/stock/news/2193099/roche-rhhby-to-acquire-obesity-drug-maker-carmot-for-2-7b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193099
Dec 04, 2023 - Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
0
An Important History Lesson for Gene-Editing Investors
https://www.fool.com/investing/2023/12/02/an-important-history-lesson-for-gene-editing-inves/?source=iedfolrf0000001
Dec 02, 2023 - Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.
0
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2192301
Dec 01, 2023 - Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
0